⌕
Arcutis Biotherapeutics · ARQT · Nasdaq
Tenet 43 · Weak
Compare
$27.33+0.66%At closeTenet 43 · Weak
$27.33+0.18 (+0.66%)
At close: Nov 17, 2026, 4:00 PM ET· Nasdaq · USD

Arcutis Biotherapeutics (ARQT) Income Statement

Is this a real, growing, cash-generative business, or a story propped up by accounting?

Sources Company filings FilingsHow we compute thisNot investment advice

1 figure withheld by our checks. Each blank figure names its reason.

Business engineGrowing fast: revenue compounds ~367.3%/yr (FY22→FY25), net margin −4.3%. Worth your attention in FY25: Share count (+157.5%) and Capex step-up ($686.0K). Both visible in the receipts below.
The four lines that matter · FY21–FY25
Revenue ($M)▲91.3%
376.1
FY22→FY25CAGR +367.3%/yr
Net income ($M)▲88.5%
−16.1
FY21→FY25CAGR —
Free cash flow ($M)▲94.4%
−6.3
capex stepped upCAGR —
Diluted EPS▲88.8%
−0.13
FY21→FY25CAGR —
What the receipts whisper · what a headline number hides
Share count
+157.5%

49.4mn → 127.2mn diluted shares since FY21. Rising share count dilutes EPS. Growth must outrun it.

Capex step-up
$686.0K

▲380% YoY in FY25, largest jump in this window; watch free-cash-flow conversion.

What the income statement says · FY21–FY25
Where every revenue dollar goes · FY25 ($M)376.1Revenue−36.7COGS339.4Gross profit−77.1R&D−274.6SG&A−12.2Op income−3.9Tax & other−16.1Net income

-4¢ of every revenue dollar becomes profit. The biggest cost lever is operating expenses.

Margin trend · direction beats level Gross Operating Net
1007550250%sector median net margin ~3%FY21FY25

Net margin -4.3% is below the sector median.

The receipt · income statement · FY21–FY25 USD thousands except per-share & ratios · hover a line for its definition
USD thousands except per-share & ratios
Line itemTTM †FY25FY24FY23FY22FY21YoYCAGR 21→25
Revenue & profitability
Revenue
508,681.0376,072.0196,542.059,606.03,686.00.0▲91.3%+367.3% (22→25)
Cost of revenue
44,871.036,695.019,128.04,987.0754.00.0▲91.8%+265.1% (22→25)
Gross profit
463,810.0339,377.0177,414.054,619.02,932.00.0▲91.3%+387.3% (22→25)
Research & development
93,855.077,051.076,420.0110,575.0182,435.0145,558.0▲0.8%−14.7%
Selling, general & admin
334,792.0274,553.0229,391.0185,145.0122,124.060,971.0▲19.7%+45.7%
Total operating expenses
428,647.0351,604.0305,811.0295,720.0304,559.0206,529.0▲15.0%+14.2%
Operating incomefeeds ROC rank
35,163.0−12,227.0−128,397.0−241,101.0−301,627.0−206,529.0▲90.5%—
Other income, net
−4,359.0−2,743.0−10,995.0−17,926.0−9,831.0173.0——
Pretax income
30,804.0−14,970.0−139,392.0−259,027.0−311,458.0−206,356.0▲89.3%—
Income tax
894.01,171.0647.03,113.00.0—▲81.0%—
Net incomePiotroski ROA ✕feeds Buffett Quality owner earnings
29,910.0−16,141.0−140,039.0−262,140.0−311,458.0−206,356.0▲88.5%—
Per share
Diluted EPSbuyback-sensitive
0.22−0.13−1.16−3.78−5.66−4.18▲88.8%—
Diluted shares (mn)
136.84127.23120.9669.3155.0349.41▲5.2%+26.7%
Margins
Gross margin87th pct in Healthcare
91.2%90.2%90.3%91.6%79.5%—▼0.0pp+10.7pp
Operating margin
6.9%−3.3%−65.3%−404.5%−8183.0%—▲62.1pp+8179.8pp
Net margin58th pct in Healthcare
5.9%−4.3%−71.3%−439.8%−8449.8%—▲67.0pp+8445.5pp
† TTM = trailing four quarters through 2026-09-30.
FY18 – FY20 · 3 more years
Unlock the full history →
3 more years of statements and CSV export are on Premium.Premium · $119/yr · 7-day trial · cancel anytimeUnlock with Premium →
Annual report filed 2026-02-25 · view filings on SEC EDGAR ↗ · reported currency USD · as-filed figures may be later restated.
Statements normalized in our fundamentals DB · Not investment advice.

What was Arcutis Biotherapeutics' revenue last fiscal year?

Arcutis Biotherapeutics reported revenue of $376.1M in fiscal 2025, up 91.3% from fiscal 2024.

What was Arcutis Biotherapeutics' net income?

Arcutis Biotherapeutics reported net income of −$16.1M in fiscal 2025, a net margin of −4.3%.

Annual and quarterly statements as filed, normalized into one comparable shape · Not investment advice.

Install Tenet on your phone

Tenet home pageMethodology© 2026 Tenet Investing Inc.

Data from Intrinio and Financial Modeling Prep.